Our study suggests that CD99-derived agonist ligands inhibit EGF-induced EGFR dimerization through impairing RhoA-Rac1 signaling-mediated reorganization of the actin cytoskeleton, thereby contributing to the suppression of breast cancer growth. Here, CD99 is linked to breast carcinoma.